Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, First-In-Human, Multicenter, Open-Label,Dose-Escalation and Extension Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1, First-In-Human, Multicenter, Open-Label,Dose-Escalation and Extension Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GQ 1005 (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Gastric cancer; HER2 positive breast cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Suzhou GeneQuantum Healthcare

Most Recent Events

  • 14 Sep 2024 According to GeneQuantum Healthcare media release, data of a novel HER2-ADC GQ1005 in HER2-expressing or HER2- mutated advanced solid tumors from this study , presented at the World Congress on Lung Cancer (WCLC) was held in San Diego, USA.
  • 10 Apr 2024 Results ( As of Oct. 13th, 2023, n=46) assessing the safety, tolerability, pharmacokinetics, and antitumor activity of GQ1005 in patients with advanced solid tumors presented at the 115th Annual Meeting of the American Association for Cancer Research
  • 06 Dec 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top